Endocyte enrolls first patient in phase 3 VISION trial of 177lu-psma-617 in prostate cancer [Seeking Alpha]
ENDOCYTE (ECYT)
Last endocyte earnings: 11/7 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.endocyte.com/investor-relations
Company Research
Source: Seeking Alpha
Endocyte enrolls first patient in phase 3 VISION trial of 177lu-psma-617 in prostate cancerEndocyte (NASDAQ:ECYT)enrolls first patient in its global phase 3 VISION trial of Lu-PSMA-617 in prostate cancer by Dr. Luke Nordquist at Urology Cancer Center in Omaha, NE.The open-label, randomized phase 3 study enrolling 750 patients will evaluate patients with progressive prostate specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC), who have received at least one novel androgen axis drug (abiraterone or enzalutamide) and at least one taxane regimen.The primary endpoint of the study is overall survival. Secondary endpoints include radiographic progression-free survival, response evaluation criteria in solid tumors response, and time to first symptomatic skeletal event.Shares are up1% premarket.Click to subscribe to real-time analytics on ECYTNow read:Institutional Top Ideas Series: Ra Capital Management »
Show less
Read more
Impact Snapshot
Event Time:
ECYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ECYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ECYT alerts
High impacting ENDOCYTE news events
Weekly update
A roundup of the hottest topics